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Background: Lung adenocarcinoma is a highly heterogeneous disease with various etiologies, prognoses, and
responses to therapy. Although genome-scale characterization of lung adenocarcinoma has been performed, a
comprehensive somatic mutation analysis of EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers has
not been conducted.
Methods: We analyzed whole exome sequencing data from 16 EGFR/KRAS/ALK-negative lung adenocarcinomas
and additional 54 tumors in two expansion cohort sets. Candidate loci were validated by target capture and Sanger
sequencing. Gene set analysis was performed using Ingenuity Pathway Analysis.
Results: We identified 27 genes potentially implicated in the pathogenesis of lung adenocarcinoma. These
included targetable genes involved in PI3K/mTOR signaling (TSC1, PIK3CA, AKT2) and receptor tyrosine kinase
signaling (ERBB4) and genes not previously highlighted in lung adenocarcinomas, such as SETD2 and PBRM1
(chromatin remodeling), CHEK2 and CDC27 (cell cycle), CUL3 and SOD2 (oxidative stress), and CSMD3 and TFG
(immune response). In the expansion cohort (N = 70), TP53 was the most frequently altered gene (11%), followed by
SETD2 (6%), CSMD3 (6%), ERBB2 (6%), and CDH10 (4%). In pathway analysis, the majority of altered genes were
involved in cell cycle/DNA repair (P <0.001) and cAMP-dependent protein kinase signaling (P <0.001).
Conclusions: The genomic makeup of EGFR/KRAS/ALK-negative lung adenocarcinomas in never-smokers is remarkably
diverse. Genes involved in cell cycle regulation/DNA repair are implicated in tumorigenesis and represent potential
therapeutic targets.Background
Lung cancer is the leading cause of cancer deaths world-
wide [1]. In 2008, 1.38 million deaths were attributed to
lung cancer, accounting for approximately 20% of
cancer-related deaths. Lung cancer is a highly heteroge-
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unless otherwise stated.response to therapy, complicating both prevention and
treatment [1]. Non-small cell lung cancer accounts for
approximately 85% of newly diagnosed lung cancers and
can be classified into two major histologic subtypes:
adenocarcinoma (approximately 50% of cases) and squa-
mous cell carcinoma (approximately 30%). Although the
majority of lung cancer cases are attributed to tobacco
smoke, approximately 25% of lung cancer cases world-
wide occur in never-smokers. Lung cancers in never-
smokers have distinct clinicopathologic characteristics
and clinical outcomes [2,3].
The discovery of driver mutations, such as epidermal
growth factor receptor (EGFR) and anaplastic lymphoma. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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personalized therapies for lung adenocarcinoma [4].
For example, erlotinib and gefitinib has been particu-
larly efficacious in patients with EGFR mutations, and
crizotinib in patients with ALK fusions [5,6]. Actionable
genetic alterations that are treatable with therapeutic
agents have been identified in approximately 50% of
lung adenocarcinomas and include mutations in EGFR,
ERBB2, KRAS, ALK, BRAF, PIK3CA, AKT1, ROS1, NRAS,
and MAP2K1 [4]. Therefore, identification of novel drug-
gable targets in the remaining 50% of lung adenocarcin-
omas is a top research priority.
Comprehensive genomic approaches are being under-
taken to accelerate the identification of new molecular
targets and increase our understanding of the critical
cellular and molecular mechanisms underlying lung
cancer [7-13]. The first comprehensive mutation profil-
ing of 623 genes in 188 adenocarcinomas identified 26
significantly mutated genes, including known onco-
genes (KRAS, EGFR, ERBB2, ERBB4, EPHA3 and other
ephrin receptor genes, KDR, and FGFR4) and tumor
suppressor genes (TP53, CDKN2A, STK11, NF1, ATM,
RB1, and APC) [7]. Recent studies using next-generation
sequencing identified new candidate driver mutations,
including RET1 rearrangements [8,14] and mutations in
CSMD3 [9], MXRA5 [10], U2AF1, RBM10, and ARID1A
[11], and DACH1, CFTR, RELN, ABCB5, and HGF [12].
Previous studies focused primarily on the identification of
new driver genes according to mutation frequency and
pattern; systematic pathway-based analysis has not been
performed. Moreover, sample sizes in previous studies
were insufficient to resolve rare driver mutations in lung
adenocarcinoma.
In this study, we analyzed exome sequencing data
from 16 EGFR/KRAS/ALK-negative tumors and paired
normal samples and an applicable expansion cohort of
54 EGFR/KRAS-negative lung adenocarcinomas to iden-
tify novel somatic mutations in lung adenocarcinomas of
never-smokers.Methods
Preparation of clinical samples
Tumor and adjacent normal lung fresh tissues were ob-
tained by surgical procedures. Clinical information in-
cluding age, sex, smoking history, tumor histology, and
tumor stage based on the seventh edition of the American
Joint Committee on Cancer staging system was col-
lected. Never-smokers were defined as patients who
had a lifelong history of smoking fewer than 100 ciga-
rettes. All patients provided informed consent. The
study was approved by the Institutional Review Board
of Severance Hospital (4-2011-0891) and conducted in
accordance with the Helsinki Declaration [15].EGFR/KRAS mutations were verified by Sanger se-
quencing and ALK rearrangement was detected by
hybridization probes. To screen for EGFR and KRAS
mutations by Sanger sequencing, we used the following
primer sequences: 5′-CAGATGTTATCGAGGTCCGA-3′
and 5′-CAAGCAGAAGACGGCATACG-3′ to detect de-
letions in exon 19 of EGFR, 5′-CAAGCAGAAGACGG
CATACG-3′ and 5′-GACCACCGAGATCTACACTC-3′
to detect the L858R mutation in exon 21 of EGFR, and 5′-
GTGACATGTTCTAATATAGTCAC-3′ and 5′-TCTATT
GTTGGATCATATTCGTC-3′ to detect mutations in
codons 12 and 13 of KRAS. ALK rearrangements were
verified using break-apart fluorescence in situ hybridization
probes (Vysis LSI ALK Dual Color, Break Apart Rearrange-
ment Probe; Abbott Molecular, Abbott Park, IL, USA).
DNA was extracted from tissues using the DNeasy Blood
& Tissue Kit (Qiagen, Valencia, CA, USA).Whole exome sequencing
Extracted DNA was sheared and a genomic library prepared
using the NEBNext kit (New England BioLabs, Inc., Ipswich,
MA, USA) according to the manufacturer’s instructions.
Exon sequences were captured using the TruSeq Exome
Enrichment Kit (Illumina, San Diego, CA, USA). Whole
exome sequencing was performed using the Illumina
HiSeq2000 platform. Sequencing data are accessible at
Sequence Read Archive ([16] accession number [SRA:
SRP022932]).Exome data analyses
The analysis flow chart is illustrated in Additional file 1:
Figure S1. The references for software packages used for
exome data analyses are summarized in Additional file 1.
Briefly, all sequenced reads were aligned to the human
reference genome National Center for Biotechnology
Information build 37 (hg19) using Novoalign. Local re-
aligning around indels and pair-end fixing was per-
formed by GATK (version 1.4-21) and Picard, and PCR
duplicates were removed using Picard. Quality scores
were recalibrated by GATK.
Three variant calling programs were used to call single
nucleotide variants: muTect (1.0.287783), VarScan (ver-
sion 2.2.11), and GATK Unified Genotyper. Indels were
called by the GATK Somatic Indel Detector with default
parameters in paired sample mode.
Mutated loci were annotated using ANNOVAR and
Polyphen2. Only non-synonymous single nucleotide var-
iants and indels in coding exons and splicing sites were
included. Known single nucleotide polymorphisms with
minor allelic frequency >5% in the 1000 Genome Project
Phase I East Asian (2012 April) and NHLBI Exome
Sequencing Project 6500 (2012 Oct) were annotated and
removed by ANNOVAR.
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The molecular-inversion probe (MIP) capture method
was used to validate 1,401 candidate loci identified in
whole exome sequencing. We designed 3,726 probes to
capture the candidate loci (Additional file 2: Table S7).
The microarray-based MIP preparation and capture ex-
periment followed MIP standard-operating procedures
with modifications in the preparation of probes (manu-
script in preparation) [17].
For MIP probe hybridization, 1 μg of genomic DNA,
1.5 μl of Ampligase buffer (Epicentre, Madison, WI,
USA), 1 μl of probe mixture (genomic DNA to probe ra-
tio, 1:90), and distilled H2O were combined to give a
total volume of 15 μl. The reaction was carried out for
5 minutes at 95°C and then the temperature was de-
creased to 60°C at a rate of 0.1°C per second followed by
incubation for 24 hours at 60°C. After addition of 0.2 μlFigure 1 Mutation summary of 16 EGFR/KRAS/ALK-negative lung adeof Phusion polymerase (New England BioLabs Inc.), 1 μl
of deoxyribonucleotide triphosphate (New England Bio-
Labs, Inc.), 0.2 μl of Ampligase buffer (Epicentre), 4
units of Ampligase DNA ligase (Epicentre), and 0.3 μl of
distilled H2O, the mixture was incubated for an add-
itional 24 hours.
PCR products were purified with a Qiagen gel extraction
kit, mixed equally based on concentrations determined
using a Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA,
USA), and sent for Illumina HiSeq2000 sequencing.
Molecular-inversion probe capture data analysis
The raw data were aligned to the human reference gen-
ome (hg19) by Novoalign. Aligned data on the position
of candidate loci were selected and transformed to
pileup format by SAMtools. The candidate loci were de-
fined as validated loci if the variant base was the same asnocarcinomas.
Table 1 Patient characteristics (N = 70)
Characteristic This study Expansion cohorta TCGA-LUADa
Number of patients 16 40 14
Age (years)
Median 58.5 63 69
Range 47 to 79 36 to 87 52 to 79
Sex (%)
Male 1 (6) 7 (17) 2 (14)
Female 15 (94) 29 (73) 12 (86)
n/a 0 4 (10) 0
Clinical stage (%)
I 13 (81) 24 (60) 9 (65)
II 0 6 (15) 2 (14)
III 3 (19) 6 (15) 3 (21)
IV 0 1 (2) 0
n/a 0 3 (8) 0
Ethnic group (%)
Caucasian 0 16 (40) 14 (100)
Asian 16 (100) 24 (60) 0
aNever-smokers with EGFR/KRAS-negative adenocarcinoma. Mb, megabase;
n/a, not available; SD, standard deviation; TCGA-LUAD, The Cancer Genome
Atlas - Lung adenocarcinoma.
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teria were satisfied: variant allele frequency in tumor
≥5%, reads supporting variant allele in normal ≤2.
Validation by Sanger sequencing
Candidate driver mutations and randomly selected
validated loci were chosen for additional validation and
appropriate primer pairs for Sanger sequencing were de-
signed (Additional file 2: Table S8). PCR products were
purified and sent for Sanger sequencing (Macrogen, Seoul,
Korea). Sequencing data were analyzed with SeqMan
(DNASTAR, Madison, WI, USA).
Canonical pathway analysis
The pathway analysis was performed through the use of
Ingenuity Pathway Analysis (Ingenuity® Systems [18]).
Pathways associated with a set of focus genes were iden-
tified from the Ingenuity Pathways Analysis library of ca-
nonical pathways. The P-value was measured to decide
the likelihood that the association between focus genes
and a given pathway was due to random chance. The
more focus genes involved, the more likely the associ-
ation is not due to random chance, and thus the more
significant the P-value. A right-tailed Fisher’s exact test
was used to calculate a P-value determining the prob-
ability of an association between the focus genes and the
canonical pathway.
Statistical analyses
Continuous clinical data (for example, age) were com-
pared using independent Student’s t-tests. Categorical data
(for example, sex, ethnicity, stage, mutation frequency)
were compared using a chi-squared test. The false-
discovery rate was corrected for multiple comparisons
using the method of Benjamini and Hochberg. All statis-
tical tests were two-tailed, and a P-value ≤0.05 was consid-
ered statistically significant. Data analyses were performed
using R statistical software version 2.15.3 [19].
Results
Exome sequencing of EGFR/KRAS/ALK-negative tumors in
never-smokers
We screened 230 surgically resected lung adenocarcin-
oma samples to identify EGFR/KRAS/ALK-negative tu-
mors in never-smokers. A total of 16 tumors (7% of all
non-small cell lung cancers) were eligible for exome se-
quencing. Tumor and normal samples had an average
sequencing depth of 51.9× and 52.0× respectively with
average coverage of 94.6% for each (Additional file 1:
Table S1). Somatic variants were validated by target-
capture sequencing (154-fold depth; average coverage of
94%) and Sanger sequencing, which had a concordance
rate of 94% with exome sequencing (Additional file 1:
Tables S2 and S3). We detected a median number of 10non-synonymous mutations and indels per tumor (range
3 to 27; Additional file 1: Table S4). The median rate of
non-synonymous mutation was 0.32 mutations per
megabase, which was comparable to that in previous re-
ports for never-smokers [11,12]. The average ratio of
transitions to transversions was 1.95; G:C→A:T transi-
tions (37%) were the most frequent followed by A:T→
G:C transitions (21%), consistent with a previous lung
cancer exome study [11]. Validated loci were further an-
alyzed for functional prediction of amino acid changes
using four different prediction algorithms (SIFT, Poly-
phen2, LRT, and Mutation Taster) (Additional file 1).
Non-synonymous somatic mutations in 16 EGFR/
KRAS/ALK-negative tumors are summarized in Figure 1
(full mutation information is provided in Additional file 1:
Table S5). Overall, 14 of 16 patients (87%) had a putative
non-synonymous mutation. Although EGFR/KRAS/ALK-
negative tumors harbored heterogeneous mutation pro-
files, somatically altered genes were functionally classified
as follows: major mitogenic and targetable pathways such
as PI3K/mTOR signaling (TSC1, PIK3CA, AKT2), receptor
tyrosine kinase signaling (ERBB4), protein tyrosine phos-
phatase (PTPRC), cell cycle (CHEK2, CDC27), and DNA
repair (PARP4); tumor suppressor pathways including
chromatin remodeling (SETD2, PBRM1, MBD2, MECP2),
Wnt signaling (CTNNB1, TGFBR2), and NF-κB signaling
(TFG); oxidative stress response (CUL3, SOD2) and differ-
entiation (SYNE2, NDRG1) (similar to lung squamous
cell carcinoma [20]); pathways not previously highlighted
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ceptor signaling (GABRD, GABRG1) and immune re-
sponse (CSMD3, SYK); as well as YTHDF1 (suggested role
in RNA binding) and PCDHB14 (role in cell adhesion).
Investigation of functional domains in altered genes
Of 32 loci shown in Figure 1, seven were found in the
Catalogue of Somatic Mutations in Cancer (COSMIC
v.65): ERBB4 V840I, PIK3CA G118D, CTNNB1 S37C,
TGFBR2 R504W, MECP2 G273V, CDC27 A273G, and
PARP4 I1039T. In addition, PIK3CA G118D (in squa-
mous cell carcinoma), CTNNB1 S37C (in adenocarcin-
oma), and MECP2 G273V (in adenocarcinoma) were
previously reported in cases of lung cancer.
To explore the functional effects of somatic variants, we
investigated functional domains in altered loci. Seventeen
loci of 27 genes shown in Figure 1 were located in func-
tional domains, including kinase domains (ERBB4 (tyrosine
kinase domain), AKT2 (serine/threonine kinase domain),
TGFBR2 (tyrosine kinase domain), SYK (protein kinase
domain)) or domains involved in oncogenic kinaseFigure 2 Distribution and pathway analysis of somatic mutations. (A)
our cohort (N = 16), the expansion cohort (N = 40), and TCGA-LUAD cohort
never-smokers. (C) Pathway analysis of altered genes in EGFR/KRAS-negativ
significant functions are shown. TCGA-LUAD, The Cancer Genome Atlas - Lactivation (TSC1 (TPR/MLP1/MLP2-like protein)); in his-
tone modification domains (SETD2 (SET domain), PBRM1
(bromo domain), MBD2 (methyl CpG binding domain),
MECP2 (methyl CpG binding domain)); in oxidative stress
response/differentiation domains (CUL3 (cullin domain),
SOD2 (superoxide dismutase domain), NDRG1 (Ndr family
domain)); in ion-channel domains (GABRD (ion-channel
binding domain), GABRG1 (ion-channel transmembrane
domain)); or were for cell cycle checkpoint proteins
(CHEK2 (fork head associated domain)).
Somatic mutations in an expansion cohort of
EGFR/KRAS-negative tumors in never-smokers
To validate and expand our mutation analysis in lung
adenocarcinoma in never-smokers, we collected an ex-
pansion dataset from five available lung adenocarcinoma
studies [9-13] and a The Cancer Genome Atlas lung car-
cinoma study [21], with no overlap with the study of
Imielinski et al. [11]. Clinical information of all patients
including sex, age, tumor stage, and ethnicity is given
in Table 1. A total of 54 EGFR/KRAS-negative tumorsVenn diagram plot comparing somatically altered genes among
(N = 14). (B) Gene profiles across EGFR/KRAS-negative tumors from
e lung adenocarcinoma from never smokers (N = 70). The most
ung adenocarcinoma.
Table 2 Mutated genes and loci information for EGFR/KRAS-negative lung adenocarcinomas from our cohort, the
expansion cohort, and The Cancer Genome Atlas cohort
Gene Mutation frequency
in our set (N = 16)
Mutation frequency in
expansion set (N = 40)
Mutation frequency in
TCGA set (N = 14)
Total
(N)
AA substitution COSMIC
v.65
Number of damage
algorithms
TP53 - 6 of 40 2 of 14 8 of 70 K93R O 4 of 4
122_122del O n/a
Y124C O 4 of 4
C203F O 4 of 4
G206S O 4 of 4
R209W O 4 of 4
E219* O 2 of 4
G295A O 4 of 4
SETD2 1 of 16 2 of 40 1 of 14 4 of 70 R839* - 1 of 2
V1576F - 3 of 3
Q1981* - 2 of 2
K2067* - 0 of 1
CSMD3 1 of 16 1 of 40 2 of 14 4 of 70 P667S O 3 of 4
M1440I - 3 of 4
K1928N - 3 of 4
Y2028C - 3 of 4
PTPRC 2 of 16 1 of 40 - 3 of 70 Y444N O 3 of 4
T453M - 3 of 4
T1176M - 4 of 4
SYNE2 1 of 16 2 of 40 - 3 of 70 2579_2580del - n/a
E3880* - n/a
E3903K O 3 of 4
GRIN2A - 3 of 40 - 3 of 70 L307Q - 3 of 4
N886S O 0 of 4
T1069M O 3 of 4
CDH10 - 2 of 40 1 of 14 3 of 70 E171K O 4 of 4
D315H O 1 of 4
R472C O 4 of 4
ERBB2 - - 3 of 14 3 of 70 E740delinsEAYVM (2) - n/a
G746delinsVC O n/a
SMAD4 - - 3 of 14 3 of 70 S242* - 1 of 2
R361S O 4 of 4
D493N O 3 of 4
CDC27 2 of 16 - - 2 of 70 I235T - 4 of 4
A273G O 3 of 4
GABRG1 2 of 16 - - 2 of 70 D43N - 2 of 4
T318S - 3 of 4
YTHDF1 2 of 16 - - 2 of 70 I492V (2) - 4 of 4
PCDHB14 2 of 16 - - 2 of 70 Y670S (2) - 2 of 3
MECP2 1 of 16 - 1 of 14 2 of 70 R168L - 2 of 3
G273V O 3 of 3
NRAS - 2 of 40 - 2 of 70 Q61H O 2 of 4
Q61K O 3 of 4
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Table 2 Mutated genes and loci information for EGFR/KRAS-negative lung adenocarcinomas from our cohort, the
expansion cohort, and The Cancer Genome Atlas cohort (Continued)
MET - - 2 of 14 2 of 70 Y1021* - 2 of 2
1027_1028del - NA
EPHA2 - 2 of 40 - 2 of 70 P147L O 4 of 4
P278S O 2 of 4
CHD2 - 2 of 40 - 2 of 70 S391fs - n/a
splicing(c.5153) O n/a
MST1 - - 2 of 14 2 of 70 406_407del - n/a
R535G - 3 of 4
ERBB4 1 of 16 - - 1 of 70 V840I O 4 of 4
PIK3CA 1 of 16 - - 1 of 70 G118D O 2 of 3
AKT2 1 of 16 - - 1 of 70 D153Y - 4 of 4
TSC1 1 of 16 - - 1 of 70 Q793* - 2 of 2
CTNNB1 1 of 16 - - 1 of 70 S37C O 4 of 4
TGFBR2 1 of 16 - - 1 of 70 R504W O 4 of 4
PBRM1 1 of 16 - - 1 of 70 E830* - 2 of 2
MBD2 1 of 16 - - 1 of 70 E373K - 4 of 4
CHEK2 1 of 16 - - 1 of 70 R191G - 3 of 4
PARP4 1 of 16 - - 1 of 70 I1039T O 4 of 4
CUL3 1 of 16 - - 1 of 70 Q516* - 2 of 2
SOD2 1 of 16 - - 1 of 70 K194E - 3 of 4
GABRD 1 of 16 - - 1 of 70 D174E - 4 of 4
NDRG1 1 of 16 - - 1 of 70 L257fs - n/a
TFG 1 of 16 - - 1 of 70 E240* - 1 of 1
SYK 1 of 16 - - 1 of 70 A400S - 4 of 4
ASPSCR1 1 of 16 - - 1 of 70 L252Q - 3 of 3
PCDHB15 1 of 16 - - 1 of 70 Y670S - 3 of 3
COSMIC, Catalogue of Somatic Mutations in Cancer; n/a, not available; TCGA, The Cancer Genome Atlas.
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non-synonymous and splicing site mutations were
extracted from a pooled dataset. The median rate of non-
synonymous mutations in EGFR/KRAS-negative never-
smokers was approximately 0.65 mutations per megabase
and the median number of non-synonymous mutations
per patient was 19.0. The average ratio of transitions to
transversions was 1.07 and G:C→A:T transitions (40%)
were the most frequent, consistent with our data.
Comparison of altered genes among the three cohorts
is shown in Figure 2. SETD2 and CSMD3 were altered
in all three cohorts (Figure 2A). Commonly altered
genes with information on affected loci, amino acid
changes, and functional predictions are summarized in
Table 2 (full information is provided in Additional file 1:
Table S6). The most frequently mutated gene was TP53,
which was altered in 11% of tumors, followed by SETD2
(6%, 4 of 70 cases), CSMD3 (6%, 4 of 70 cases), and
ERBB2 (6%, 4 of 70 cases). PTPRC, SYNE2, GRIN2A,CDH10, and SMAD4 were each altered in 3 of 70 cases
(4%). SETD2 interacts with p53 and regulates genes
downstream of p53 in addition to increasing p53 stabil-
ity [22]. Mutations in SETD2 were nonsense mutations
in three cases and missense mutation in one case. The
missense mutation V1576F is located in the SET do-
main; one nonsense mutation, R839*, is a truncating
mutation upstream of the SET domain, and two non-
sense mutations, Q1981* and K2067*, are truncating
mutation upstream of the WW domain. In addition to
known cancer driver genes such as ERBB2 (6% of cases),
NRAS (3%), MET (3%), PIK3CA (1%), AKT2 (1%), TSC1
(1%), and ERBB4 (1%), several putative cancer genes
were identified, such as PTPRC [23], SYNE2 [24],
GRIN2A [25], and CDH10 [26]. The mutation pattern is
summarized in Figure 2B.
Pathway analysis of 1,760 genes that were altered in 70
EGFR/KRAS-negative tumors of never-smokers revealed
alterations in genes related to DNA repair and the cell
Figure 3 Significantly mutated genes in EGFR/KRAS-negative
lung adenocarcinomas from never-smokers (N = 70).
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or G2/M checkpoint regulation, and non-homologous end
joining (Figure 2C). The most significantly enriched
pathway was cAMP-dependent protein kinase A signal-
ing, which can activate the mitogen-activated protein
kinase cascade in lung adenocarcinoma [27]. Other
enriched functions of altered genes were calcium trans-
port (P = 0.006), axonal guidance (P = 0.015), and Ephrin
A signaling (P = 0.031).
Discussion
The somatic mutation profile in lung adenocarcinomas
lacking targetable EGFR or KRAS mutations or ALK rear-
rangements in never-smokers is highly complex. Our ex-
ome analysis of 70 tumors identified several common
mutations involving the known cancer genes TP53, NRAS,
ERBB2, PIK3CA, and CTNNB1, but also mutations in
SETD2, CSMD3, PTPRC, and SYNE2 (Figure 3).
SETD2 (mutated in 6% of cases) is a histone methyl-
transferase that is involved in transcriptional elongation
and chromatin remodeling. Interaction with p53 is facili-
tated by the SET and WW domains and might increase
p53 stability [22]. Interestingly, SETD2 and TP53 muta-
tions were mutually exclusive in lung adenocarcinoma of
never-smokers (Figure 2B). CSMD3 (mutated in 6% of
cases) is a transmembrane protein with CUB and sushi
multiple domains that is thought to function in protein-
protein interactions and the immune response. Recent
studies showed that loss of CSMD3 increases prolifera-
tion of airway epithelial cells [9] and may be involved in
tumorigenesis in lung cancer. In our study, missense
mutations (P667S, M1440I, K1928N, and Y2028C) in
CSMD3 were predicted to be deleterious to protein
function. PTPRC (mutated in 4% of cases) is a member
of the protein tyrosine phosphatase family and regulates
a variety of cellular processes including cell growth, dif-
ferentiation, and tumorigenesis. PTPRC regulates the
JAK/STAT signaling pathway and functional defects can
activate JAK/STAT signaling [23]. We observed three mis-
sense mutations (Y444N, T453M, T1176M) in PTPRC, all
of which were predicted to be deleterious. SYNE2 plays a
role in cadherin-mediated cell-cell adhesion and regulates
the Wnt signaling pathway [24].
We identified several targetable pathways in EGFR/
KRAS/ALK-negative lung adenocarcinoma including PI3K/
mTOR signaling (TSC1, PIK3CA, AKT2), receptor tyrosine
kinase signaling (ERBB4), cell cycle regulation (CHEK2,
CDC27), and DNA repair (PARP4). PI3K pathway in-
hibitors and cell cycle inhibitors are actively under in-
vestigation for lung adenocarcinoma in preclinical and early
phase clinical trials [28,29]. A current mutation screening
program for tailored targeted therapies is also on-going in
1,000 patients with advanced lung adenocarcinoma based
on 10 single driver mutations: KRAS (25%), EGFR (23%),ALK rearrangements (6%), BRAF (3%), PIK3CA (3%), MET
amplifications (2%), ERBB2 (1%), MEK1 (0.4%), NRAS
(0.2%), and AKT1 (<0.1%) [30]. Additional genomic alter-
ations will be incorporated in a comprehensive manner
based on next-generation sequencing data.
More than 200 putative cancer-causing genes have been
identified in recent genomic landscape studies using next-
generation sequencing technology, and several cellular
processes not previously implicated in cancer have been
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ubiquitination [31,32]. We identified alterations in genes
involved in chromatin remodeling (PBRM1, SETD2), oxi-
dative stress (CUL3, SOD2), immune response (CSMD3,
SYK), and gamma-aminobutyric acid receptor signaling
(GABRD, GABRG1) in lung adenocarcinoma. Interest-
ingly, although somatic mutation is rare in EGFR/KRAS/
ALK-negative lung adenocarcinoma of never-smokers, the
PCDHB14 (cell adhesion) Y670S mutation and YTHDF1
(RNA binding) I492V mutations were each found in
two cases (12.5%). Future studies to elucidate the role
of these newly implicated functions in tumorigenesis
are warranted.
Conclusions
We identified novel somatic mutations in EGFR/KRAS/
ALK-negative lung adenocarcinoma in never-smokers and
investigated the mutation frequency of altered genes.
EGFR/KRAS/ALK-negative lung adenocarcinoma in never-
smokers is highly heterogeneous at the somatic mutation
level. However, most of the altered genes were involved in
the cell cycle, and might represent novel therapeutic tar-
gets in lung adenocarcinoma. Future research on the func-
tional role of chromatin remodeling, oxidative stress/
differentiation, and the immune response will enhance our
understanding of the mechanisms of tumorigenesis.
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